Forbion Closes Third Fund, 'Agnostic' On When To Invest
This article was originally published in Scrip
Forbion Capital Partners has conducted the final closing of its third main fund Forbion Capital Fund III (FCF III), raising a total of €183m. Despite the Netherlands-based venture firm closing its last fund - FCF II - in 2010 when the investment climate was less friendly, Forbion's investment strategy remains much the same. Managing partner Sander Slootweg explains why.
You may also be interested in...
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.